Researchers at UC San Diego have developed advanced deep learning techniques that could revolutionize treatment planning for ...

AdventHealth Daytona Beach's new wellness center does more than offer integrative therapies such as yoga, acupuncture and massage — it provides them to cancer patients for free. The SherryStrong ...

Sun Pharma to acquire Checkpoint Therapeutics for $4.10 per share, with potential CVR. FDA approves Unloxcyt, the first PD-L1 blocker for advanced cSCC.

The province and the federal government have officially signed an agreement to make diabetes medication and hormone replacement therapy for menopause free within the next year. Federal Health Minister ...

Kura Oncology, Inc. (NASDAQ ... Analysts are anticipating this data as a significant catalyst for the company’s stock performance. The ongoing Phase 1 KOMET-007 combination trial has also ...

Tesla is the worst-performing MAG 7 stock in 2024, down 30.18% year to date, with bearish technical signals. Tesla's high P/E and lagging revenue growth contrast sharply with Nvidia and Meta’s ...

Even the best stock pickers ... for example - Kura Oncology has 2 warning signs we think you should be aware of. For those who like to find winning investments this free list of undervalued ...

Shares of Pyxis Oncology (NASDAQ:PYXS) traded higher in the premarket on Wednesday after the U.S. FDA issued its Fast Track Designation for the company’s lead candidate, PYX-201, targeted at ...

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate The Oncology Institute ... clinical trial, radiation, outpatient blood product ...

Investors are bullish on the stock as cretostimogene’s unique product profile distinguishes it from the investigational and current NMIBC treatments. CG Oncology, Inc. (NASDAQ:CGON) has $540.7 ...

aDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA bDepartment of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer ...

So, the gem in its oncology franchise is Breyanzi ... you will learn why I believe BMY is an attractive stock for long-term investors. On February 6, Bristol-Myers Squibb (NYSE:BMY) released ...